Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisoprolol vs Atenolol in Essential Hypertension
NCT01251146Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2010
- Primary completion
- Feb 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bisoprolol in essential hypertension (2 arms), sponsored by Merck KGaA. Primary endpoints: Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal at Week 6 and Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up at Week 8. Started Nov 2010; status: completed.
02
Drugs
bisoprolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01251146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251146.